Study #2024-1539
A phase 3 randomized, double-blind, placebo-controlled, study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2ARearrangements or NPM1Mutations who are ineligible for intensive chemotherapy
MD Anderson Study Status
Enrolling
Treatment Agent
Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Placebo
Description
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia, Myeloid, Acute
Study phase:
Phase III
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.